Every One of These Peptides Started as an Extract of the Organ It's Named After

Read down the list and the naming convention gives the whole thing away. Bronchogen, bronchial. Cardiogen, cardiac. Cartalax, cartilage. Vesugen, vascular.

Those aren't marketing names. They're a record of where each compound came from, and the story behind that convention is the most interesting thing about the series.

It began with extracts, not with design

The program didn't start by designing peptides. It started by pulling material out of tissue.

The early work used substances called cytomedins: low molecular weight material isolated from animal tissue extracts, showing peptide-like activity. Thymalin, a polypeptide complex from calf thymus, was the first preparation of the lot.

The synthetic compounds came afterwards. More defined short peptides were made, intended to reproduce the activity of the substances that had been identified in those extracts.

That order is the important part. The synthetic series is a reconstruction of something first found in tissue. It is not a set of molecules designed from scratch against a chosen target, which is how most modern compounds arrive.

They are extraordinarily short

It's worth pausing on the size, because it's easy to skim past. These are peptides of two to four amino acids.

Vilon is a dipeptide. Two residues, and that's the whole molecule. Most things in a peptide catalogue run to dozens of residues, and some to hundreds. Two amino acids is roughly the smallest a thing can be while still being called a peptide at all.

The origin is also the central claim

This is where the extraction history stops being background and becomes the entire argument.

The originating group proposes that each peptide preferentially influences the tissue its parent extract was derived from. That is the logic of the whole series. A cartilage extract yields a cartilage peptide, a bronchial extract a bronchial one, and so on down the bioregulator range.

It's an elegant proposition, and it follows naturally from how the compounds were found in the first place. Our own write-up is clear about what would settle it: independent studies of tissue specificity and cross-reactivity, which would have to come from outside the program that produced the hypothesis.

Two facts stated side by side, and deliberately not joined

Here's the part I find most interesting, and it's about how the material is handled rather than what it says.

The first fact: the original peptide identification methods used are not equivalent to current sequencing and identification standards. That's a plain statement about decades-old technique, and it would have been easy to leave out.

The second fact: reported peptide sequences for several of these compounds differ across sources, which makes comparison harder.

Put those next to each other and the obvious move is to say the first explains the second. Our page explicitly declines to make it. It states both, says it does not explain why the sequences differ, and notes the methods point separately.

That restraint is the right call and it's rarer than it should be. A tempting explanation that hasn't actually been demonstrated is still just a tempting explanation. Joining those two facts would have produced a causal claim nobody has established, in a piece whose whole job is to be careful about what has been shown.

Where the science went from there

The distinctive proposal that grew out of all this is that peptides this short get into the cell nucleus and interact with DNA directly, in a sequence-selective way, without going through a cell-surface receptor at all.

Fedoreyeva and colleagues reported in 2011 that fluorescently labeled short peptides, Epitalon among them, entered the nuclei of cultured cells. Binding measurements across a panel of DNA sequences differed from peptide to peptide, and those differences tracked each peptide's own sequence.

Khavinson and colleagues reported in 2014 on Bronchogen, describing altered expression across a panel of genes tied to bronchial tissue identity, alongside interaction with DNA in laboratory assays.

Both are cell-level and test-tube findings. They support a proposed mechanism rather than establishing a pathway, which is exactly how the full write-up frames them. That framing is worth keeping in mind whenever the mechanism gets described elsewhere as settled.

The result the program published anyway

One animal study deserves singling out, for the way it was reported rather than for what it found.

Anisimov and colleagues followed mice given monthly courses of Epitalon from three months of age until natural death. Mean lifespan did not change.

Other measures did. Chromosome aberrations in bone marrow fell by 17.1 percent, and the age-related switching-off of oestrous function slowed. But the headline number a geroprotector program would most want to report came back flat, and it went into the record flat.

Our own page treats that absent lifespan effect as a useful check on broader claims made elsewhere, which is a fair reading. It's also a study that could have buried an inconvenient primary result and didn't.

The caveat that applies to all of it

The great majority of this research, and nearly all of the direct DNA-interaction mechanism work, originates from the same program and its collaborators. Independent replication in other laboratories has been limited, and the proposed sequence-selective DNA binding is not a broadly validated mechanism in mainstream molecular biology.

That isn't a verdict. It's the reason the tissue-specificity claim above still needs outside work before it can be called established.

Why the names still matter

The convention isn't decoration. It's a fossil of the method.

Each name records the organ its original extract came from, and that origin is the basis for the claim about which tissue the peptide is supposed to influence. Understand where the names came from and you understand what makes the series appealing. You also understand the specific thing somebody outside the program would have to demonstrate for it to hold.

These are research compounds, supplied for laboratory research use only.